This systematic review summarizes mechanistic and clinical evidence for N-acetylcysteine in Parkinson's disease, suggesting its role as a potential treatment.
Background Parkinson's disease (PD) involves progressive motor and non-motor decline, linked to oxidative stress and glutathione depletion. N-acetylcysteine (NAC), a glutathione precursor and antioxidant, is a potential disease-modifying therapy.
No takes yet. Share an insight, caveat, or question.
Mohammad et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: